Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates |
Apr 2008 | £7,210 | 100% |
| Pipeline Insight: Colorectal Cancer Growing trend towards personalized medicine |
Oct 2009 | £7,210 | 99% |
| Pipeline Insight: Biologic Targeted Cancer Therapies Next generation jostles for market position |
Dec 2009 | £7,210 | 99% |
| Stakeholder Opinions: Ovarian Cancer Approaching the era of molecular targeted therapy |
Jul 2010 | £2,405 | 99% |
| Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
Apr 2008 | £7,210 | 96% |
| Pipeline Insight: Small Molecule Targeted Cancer Therapies New targets set to drive growth |
Apr 2010 | £7,210 | 96% |
| Global Pipeline Review & Analysis of Hematological Malignancies | Mar 2007 | £1,960 | 93% |
| Stakeholder Opinions: Hepatocellular cancer | Dec 2010 | £2,405 | 92% |
| Decoding Big Pharmas R&D Strategy in Oncology | Sep 2007 | £3,050 | 91% |
| Decoding Big Pharma's R&D Strategy in Oncology | Sep 2007 | £1,630 | 91% |
| Prostate Cancer - A Therapeutic & Competitive Insight Pipeline Update 2010 |
Jan 2010 | £1,245 | 91% |
| Stakeholder Opinions: Primary Brain Cancer | Jul 2007 | £2,400 | 90% |
| Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
Apr 2006 | £1,900 | 90% |
| Lung Cancer Therapeutics Market Outlook and Pipeline Analysis | Nov 2009 | £945 | 88% |
| Exiqon AS Product Pipeline Analysis | Jan 2009 | £475 | 86% |
| Stakeholder Opinions: Gynecological Cancers Niche opportunities in advanced disease |
Dec 2006 | £2,400 | 86% |
| Gen-Probe Incorporated Product Pipeline Analysis | Jan 2009 | £475 | 86% |
| Pipeline Insight: Cancer Overview Gastrointestinal, Skin, Sarcomas |
Jan 2009 | £7,210 | 86% |
| Stakeholder Opinions: Sarcomas | Dec 2008 | £2,405 | 86% |
| Biomedical Imaging From Drug Target Discovery to Medical Diagnostics |
Dec 2008 | £2,370 | 85% |
| Innovations in Protein Kinase Therapies: Company pipelines, therapeutic applications and market forecasts | May 2009 | £2,425 | 85% |
| The Executive Guide to Molecular Imaging | Jul 2007 | £595 | 84% |
| Gene Therapy | Jan 2011 | £2,845 | 84% |
| Biomarkers The Expanding Global Market |
Jan 2007 | £2,760 | 83% |
| Advances in Molecular Imaging Companies and Technologies that are driving change |
Feb 2010 | £695 | 81% |
| Stakeholder Insight: Gastric Cancer | Sep 2010 | £9,615 | 81% |
| Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
Feb 2007 | £1,820 | 81% |
| Delivering RNAi-Based Therapeutics & Diagnostics Challenges & Opportunities |
Jul 2009 | £945 | 81% |
| Tumor Markers Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 |
May 2011 | £2,215 | 81% |
| Top 7 Cancer Indications Therapeutic & Competitive Insights |
Jan 2007 | £5,770 | 80% |
